Fig. 4
From: Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma
The prognostic impact of adjuvant immunotherapy on prognosis. (A) Unadjusted disease-free survival in patients with pathological high-risk MIUC. (B) Unadjusted overall survival in patients with pathological high-risk MIUC. (C) The ATT-based IPTW-adjusted disease-free survival in patients with pathological high-risk MIUC. (D) The ATT-based IPTW-adjusted overall survival in patients with pathological high-risk MIUC.
